Melphalan for Use With the Hepatic Delivery System Treatment in Patients With Unresectable Hepatocellular Carcinoma or Intra Hepatic Cholangiocarcinoma

• Register: ClinicalTrials.gov
• Last refreshed on: 24 October 2022
• Main ID: NCT02415036
• Date of registration: 08/04/2015
• Prospective Registration: No
• Primary sponsor: Delcath Systems Inc.
• Public title: Melphalan for Use With the Hepatic Delivery System Treatment in Patients With Unresectable Hepatocellular Carcinoma or Intra Hepatic Cholangiocarcinoma
• Scientific title: An International Multi-center Phase 2 Study to Evaluate the Efficacy and Safety of Melphalan Hydrochloride for Injection for Use With the Hepatic Delivery System Treatment in Patients With Unresectable Hepatocellular Carcinoma or Intra Hepatic Cholangiocarcinoma
• Date of first enrolment: June 2014
• Target sample size: 17
• Recruitment status: Terminated
• URL: https://clinicaltrials.gov/show/NCT02415036
• Study type: Interventional
• Study design: Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
• Phase: Phase 2

Countries of recruitment

Germany

Contacts

• Name: Johnny John, MD
• Affiliation: Delcath Systems

Key inclusion & exclusion criteria

Inclusion Criteria:

Patients with HCC must meet all of the following criteria for study entry:

1. HCC diagnosed by tissue or imaging study.

2. Unresectable HCC without clinically significant extra hepatic disease (minor lesions
[= 1 cm and not consistent with metastatic disease] acceptable) based on computed
tomography (CT).

3. At least one target lesion based on mRECIST. In patients with prior loco-regional
therapy, the target lesion(s) must be located in area(s) outside previous treatment or
must have progressed after prior treatment if located within previous treatment field.

4. Child-Pugh Class A.

5. ECOG PS 0-1.

6. No prior radiation therapy to the liver including Y90-, I131-based loco-regional
therapy. Prior loco regional therapy, including resection, based on other technology
for HCC, if any, must have been completed at least 4 weeks prior to baseline imaging.

7. Age = 18 years.

8. Signed informed consent.

Patients with ICC must meet all of the following criteria for study entry:

1. ICC diagnosed by tissue or imaging study.

2. Unresectable ICC without clinically significant extra hepatic disease (minor lesions
[= 1 cm and not consistent with metastatic disease] acceptable) based on CT.

3. At least one target lesion based on mRECIST. In patients with prior loco regional
therapy, the target lesion(s) must be located in area(s) outside previous treatment or
must have progressed after prior treatment if located within previous treatment field.

4. Child-Pugh Class A.

5. ECOG PS 0-1.

6. No prior radiation therapy to the liver including Y90 , I131 based loco regional
therapy. Prior loco regional therapy, including resection, based on other technology
for ICC, if any, must have been completed at least 4 weeks prior to baseline imaging.

7. Age = 18 years.

8. Signed informed consent.

Exclusion Criteria:

For the HCC cohort, patients for whom transplantation, radiofrequency ablation (RFA),
transarterial chemoembolization (TACE), or systemic treatment with sorafenib are better
therapeutic options are to be excluded from study entry.

Additionally, for both the HCC and ICC cohorts, patients who meet any of the following
criteria will be excluded from study entry:

1. Greater than 50% tumor burden in the liver by imaging.

2. History of orthotopic liver transplantation, Whipple's procedure, hepatic vasculature
incompatible with perfusion, hepatofugal flow in the portal vein or known unresolved
venous shunting.

3. Evidence of ascites on imaging study, or the use of diuretics for ascites.

4. Clinically significant encephalopathy.

5. History of, or known, hypersensitivity to any components of melphalan or the
components of the Melphalan/HDS system.

6. Known hypersensitivity to heparin or the presence of heparin-induced thrombocytopenia.

7. Received an investigational agent for any indication within 30 days prior to first
treatment.

8. Not recovered from side effects of prior therapy to = Grade 1 (according to National
Cancer Institute [NCI] CTCAE version 4.03). Certain side effects that are unlikely to
develop into serious or life-threatening events (e.g. alopecia) are allowed at > Grade
1.

9. Those with New York Heart Association functional classification II, III or IV; active
cardiac conditions including unstable coronary syndromes (unstable or severe angina,
recent myocardial infarction), worsening or new-onset congestive heart failure,
significant arrhythmias and severe valvular disease must be evaluated for risks of
undergoing general anesthesia.

10. History or evidence of clinically significant pulmonary disease that precludes the use
of general anesthesia.

11. Uncontrolled diabetes mellitus, hypothyroidism, or hyperthyroidism.

12. Active infection, including Hepatitis B and Hepatitis C infection. Patients with
anti-hepatitis B core antigen (HBc) positive, or hepatitis B surface antigen (HBsAg)
but viral deoxyribonucleic acid (DNA) negative are exception(s).

13. History of bleeding disorders.

14. Brain lesions with a propensity to bleed.

15. Known varices at risk of bleeding, including medium or large esophageal or gastric
varices, or active peptic ulcer.

16. Previous malignancy within 3 years prior to enrollment, except for curatively-treated
basal cell or squamous cell carcinoma of the skin, cervical carcinoma in situ, bladder
carcinoma in situ or breast cancer in situ.

17. Inadequate hematologic function as evidenced by any of the following:

1. Platelets < 90,000/µL

2. Hemoglobin < 8 g/dL, independent of transfusion or growth factor support

3. Neutrophils < 1,500 cells/µL.

18. Serum creatinine > 1.5 mg/dL.

19. Inadequate liver function as evidenced by any of the following:

1. Total serum bilirubin = 2.0 mg/dL

2. Prothrombin time (PT)/international normalized ratio (INR) > 1.5

3. Aspartate aminotransferase (AST) > 10 times the upper limit of normal (ULN) or
alanine aminotransferase (ALT) > 5 times ULN

4. Serum albumin < 3.0 g/dL.

20. Known alcohol abuse.

21. For female subjects of childbearing potential (i.e., have had a menstrual period
within the past 12 months): a positive serum pregnancy test (ß-human chorionic
gonadotropin [ß HCG]) within 7 days prior to enrollment; or unwilling or unable to
undergo hormonal suppression to avoid menstruation during treatment.

22. Sexually active females of childbearing potential and sexually active males with
partners of reproductive potential: unwilling or unable to use appropriate
contraception from screening until at least 30 days after last administration of study
treatment.



Age minimum: 18 Years
Age maximum: N/A
Gender: All

Health Condition(s) or Problem(s) studied

Hepatocellular Carcinoma

Intrahepatic Cholangiocarcinoma

Intervention(s)

Device: Delcath Hepatic Delivery System

Drug: Melphalan

Primary Outcome(s)

Objective response rate in percentage of Melphalan/HDS treatment [Time Frame: 2 years]

Secondary Outcome(s)

Progression free survival in months of patients receiving Melphalan/HDS treatment. [Time Frame: 2 years]

Number of patients with adverse events after treatment with Melphalan/HDS. [Time Frame: 2 years]

Secondary ID(s)

PHP-HCC-202

Source(s) of Monetary Support

Please refer to primary and secondary sponsors